CRISPR
Also known as: CRISPR-Cas9, CRISPR gene editing
CRISPR is a gene-editing technology that lets scientists find a specific spot in DNA and cut or change it, using a guide molecule and an enzyme such as Cas9.
It's faster, cheaper, and more precise than earlier gene-editing methods. While CRISPR has already produced an approved treatment for sickle cell disease and is used throughout biology research, its power also raises hard ethical questions, especially about editing embryos.
CRISPR, explained at three levels
At home
Think of DNA as a very long instruction book and CRISPR as a search tool paired with scissors. You type in a short sequence, and the tool scans the book until it finds an exact match, then cuts there. The cell notices the cut and repairs it, which can switch that instruction off or, if scientists supply a corrected sentence, write in the fix.
At work
CRISPR is a gene-editing technology that lets researchers target and change specific DNA sequences cheaply and quickly. It is used across biology research, drug discovery, agriculture, and now approved therapies, such as Casgevy for sickle cell disease. For businesses, it shortened the time and cost of building disease models and testing drug targets, and opened a new class of one-time genetic treatments.
At home
CRISPR-Cas9 has two parts. The guide RNA is a short strand, about 20 letters long, that matches the target DNA. Cas9 is an enzyme that follows the guide and cuts both strands of DNA at that spot. The cell then repairs the break. Its quick repair method often adds or loses a few letters, which switches the gene off. Its slower method copies a supplied template, which lets scientists insert a precise correction.
At work
Therapeutic CRISPR is delivered two ways. Ex vivo, cells are removed, edited in a lab, and returned, as with Casgevy, where blood stem cells are edited to restart fetal hemoglobin production. In vivo, editing tools are delivered inside the body, usually in lipid nanoparticles that travel to the liver. Base editors swap a single DNA letter without cutting both strands, and prime editors rewrite short stretches, reducing the unpredictable repairs that follow a double-strand break.
At home
CRISPR's guide can tolerate small mismatches, so Cas9 sometimes cuts similar-looking sites elsewhere, called off-target editing. Even at the right site, repairs can delete larger chunks than intended. Edits to an adult's blood or liver cells stay in that person, but edits to embryos would pass to every future generation without their consent. While both use the same tool, in my opinion they are completely different ethical questions and deserve different rules.
At work
Clinical CRISPR faces four constraints. Delivery: viral vectors and lipid nanoparticles reach some tissues, mainly blood and liver, far better than others. Safety: off-target edits, large on-target deletions, and immune responses to Cas proteins. Manufacturing: ex vivo therapies need conditioning chemotherapy and patient-specific cell processing. Cost: Casgevy lists at about US$2.2 million in the US. Patent disputes over Cas9 rights persist, and regulators are drafting pathways for personalized n-of-1 editing therapies.
Real-world examples
At home
Carlos read about a teenager with sickle cell disease who received a CRISPR-based treatment. The patient had faced frequent painful crises for years, and after treatment no longer needed regular blood transfusions.
At work
Lena is a research scientist at a Toronto biotech company. Her lab uses CRISPR screens to switch off thousands of genes one by one in cancer cells, identifying which ones the cancer depends on as possible drug targets.
How it compares
| feature | CRISPR-Cas9 | Base editing | Prime editing |
|---|---|---|---|
| How it changes DNA | Cuts both DNA strands | Changes a single DNA letter | Rewrites short sequences |
| Precision | High, with repair variability | Very high for specific changes | Very high, more flexible |
| Maturity | Approved therapies | Clinical trials and early treatments | Early clinical trials |
| Main risk | Unintended edits at cut sites | Off-target base changes | Delivery challenges |
Newer editors trade the scissors for a pencil, changing DNA more gently.
For analysts
For health systems, gene-editing cures create budget problems: one-time treatments costing millions. I'd watch outcome-based payment models, where payers pay over time if the treatment keeps working.
History & origin
Scientists noticed unusual repeated DNA sequences in bacteria in the late 1980s, and in the 2000s learned they were part of a bacterial immune system against viruses. In 2012, Jennifer Doudna and Emmanuelle Charpentier showed CRISPR-Cas9 could be programmed to cut DNA at chosen sites, and Feng Zhang's team demonstrated editing in human cells in 2013; Doudna and Charpentier won the 2020 Nobel Prize in Chemistry. In 2018, He Jiankui shocked the world by announcing gene-edited babies in China and was later imprisoned. Casgevy, a CRISPR therapy for sickle cell disease and beta thalassemia, was approved in the UK and US in late 2023 and by Health Canada in 2024. In 2025, doctors in Philadelphia treated a baby with a personalized base-editing therapy designed for his rare condition. In my view, CRISPR's medical promise is real, but its first cures cost millions per patient, so access is the next frontier.